Turtle Creek Wealth Advisors LLC Has $5.50 Million Holdings in Johnson & Johnson $JNJ

Turtle Creek Wealth Advisors LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 12.9% in the first quarter, HoldingsChannel reports. The firm owned 22,513 shares of the company’s stock after acquiring an additional 2,578 shares during the period. Turtle Creek Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $5,503,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of JNJ. USAdvisors Wealth Management LLC acquired a new position in Johnson & Johnson during the 1st quarter worth about $207,000. New York State Teachers Retirement System raised its stake in shares of Johnson & Johnson by 0.5% in the first quarter. New York State Teachers Retirement System now owns 1,984,293 shares of the company’s stock worth $485,041,000 after acquiring an additional 10,793 shares during the last quarter. Gordian Advisors LLC lifted its position in shares of Johnson & Johnson by 1.3% during the first quarter. Gordian Advisors LLC now owns 4,356 shares of the company’s stock worth $1,065,000 after purchasing an additional 58 shares in the last quarter. Flagstone Financial Management grew its stake in shares of Johnson & Johnson by 6.9% during the first quarter. Flagstone Financial Management now owns 1,936 shares of the company’s stock valued at $473,000 after purchasing an additional 125 shares during the last quarter. Finally, Sierra Summit Advisors LLC increased its holdings in shares of Johnson & Johnson by 8.2% in the first quarter. Sierra Summit Advisors LLC now owns 15,359 shares of the company’s stock valued at $3,754,000 after purchasing an additional 1,166 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the company’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the sale, the executive vice president directly owned 114,288 shares of the company’s stock, valued at $27,560,551.20. This represents a 8.05% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Trading Up 3.5%

Shares of JNJ stock traded up $9.20 during trading hours on Tuesday, reaching $268.53. The company had a trading volume of 1,799,409 shares, compared to its average volume of 8,414,570. Johnson & Johnson has a 1-year low of $154.21 and a 1-year high of $268.88. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77. The firm has a market cap of $646.40 billion, a price-to-earnings ratio of 31.02, a P/E/G ratio of 2.58 and a beta of 0.24. The company has a 50 day moving average of $233.72 and a 200 day moving average of $231.37.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping analysts’ consensus estimates of $2.68 by $0.02. The business had revenue of $24.06 billion during the quarter, compared to analysts’ expectations of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The firm’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, equities research analysts anticipate that Johnson & Johnson will post 11.57 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th were given a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. The ex-dividend date was Tuesday, May 26th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s dividend payout ratio is presently 61.97%.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on JNJ. JPMorgan Chase & Co. boosted their target price on Johnson & Johnson from $250.00 to $260.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 15th. Daiwa Securities Group raised their price target on Johnson & Johnson from $237.00 to $246.00 and gave the company an “outperform” rating in a report on Thursday, April 16th. Guggenheim boosted their price objective on Johnson & Johnson from $266.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, June 26th. Wells Fargo & Company upped their target price on shares of Johnson & Johnson from $240.00 to $263.00 and gave the company an “overweight” rating in a research report on Wednesday, April 15th. Finally, HSBC set a $290.00 target price on shares of Johnson & Johnson and gave the company a “buy” rating in a research note on Monday. Twenty analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $257.13.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.